Discounted Cash Flow (DCF) Analysis Levered

Onconova Therapeutics, Inc. (ONTX)

$1.34

-0.11 (-7.59%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 0.791.232.180.230.230.250.280.310.340.37
Revenue (%)
Operating Cash Flow -23.82-22.70-20.83-23.08-19.49-12.21-13.50-14.93-16.50-18.25
Operating Cash Flow (%)
Capital Expenditure ---0.06-0.02-0.01-0.01-0.01-0.01-0.02-0.02
Capital Expenditure (%)
Free Cash Flow -23.82-22.70-20.89-23.09-19.50-12.22-13.51-14.94-16.52-18.26

Weighted Average Cost Of Capital

Share price $ 1.34
Beta 1.619
Diluted Shares Outstanding 16.83
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 10.405
Total Debt -
Total Equity 22.56
Total Capital -
Debt Weighting -
Equity Weighting -
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 0.791.232.180.230.230.250.280.310.340.37
Operating Cash Flow -23.82-22.70-20.83-23.08-19.49-12.21-13.50-14.93-16.50-18.25
Capital Expenditure ---0.06-0.02-0.01-0.01-0.01-0.01-0.02-0.02
Free Cash Flow -23.82-22.70-20.89-23.09-19.50-12.22-13.51-14.94-16.52-18.26
WACC
PV LFCF -----
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -18.63
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -55.07
Equity Value -
Shares Outstanding 16.83
Equity Value Per Share -